| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
|
Lancet
|
2011
|
4.79
|
|
2
|
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
|
J Clin Oncol
|
2007
|
1.93
|
|
3
|
Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
|
Chest
|
2013
|
1.72
|
|
4
|
Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases.
|
Ann N Y Acad Sci
|
2013
|
1.41
|
|
5
|
Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
|
Clin Breast Cancer
|
2008
|
1.04
|
|
6
|
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
|
J Thorac Oncol
|
2012
|
0.91
|
|
7
|
Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison.
|
Exp Hematol Oncol
|
2013
|
0.86
|
|
8
|
Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors.
|
Cancer Chemother Pharmacol
|
2007
|
0.86
|
|
9
|
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study.
|
Br J Haematol
|
2014
|
0.76
|